Plasma vertical position control in the COMPASS–D tokamak by Vyas, P

Disease Models and Mechanisms announces a new editor-in-chief by Vyas, P

Myelodysplastic and myeloproliferative diseases in children: current concepts by Vyas, P

Changing treatment changing prognosis of mutations by Vyas, P

Poorer clinical outcomes for black patients with AML: a wake-up call for better data and greater understanding of cancer outcomes in all ethnic groups by Vyas, P

Targeting HIF function: the debate continues. by Vyas, P

Genetic and non-genetic mechanisms of inflammation may promote transformation in leukemia by Vyas, P

Sowing the seeds of leukemia before birth by Roberts, I, Vyas, P

Enigmatic variation. by Roberts, I, Vyas, P

BCL-2 inhibitor and conventional chemotherapy combinations for acute myeloid leukemia: shifting from the unfit to the fit patient with AML by Ossenkoppele, G, Vyas, P

Clever leukemic stem cells branch out. by Vyas, P, Jacobsen, SE

JAK mutations in Down syndrome - associated transient myeloproliferative disorder and acute megakaryocytic leukemia by Vyas, P, Crispino, J

Characterization of the hemopoietic defect in early stages of the myelodysplastic syndromes. by Vyas, P, Sternberg, A

Good news for the aging population? by Vyas, P, Higgs, D

Bone marrow transplantation. by Vyas, P, Goldstone, A

Shall we dance: evolving partnerships of targeted therapies for AML by Perl, AE, Vyas, P

The inflammasome: more than a protective innate immune mechanism by Stoilova, B, Vyas, P

From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia by Jakobsen, N, Vyas, P

Molecular insights into Down syndrome-associated leukemia. by Vyas, P, Crispino, J

Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis. by Vyas, P, Roberts, I